Ignite Creation Date:
2025-12-25 @ 1:40 AM
Ignite Modification Date:
2025-12-27 @ 11:17 PM
Study NCT ID:
NCT01182194
Status:
COMPLETED
Last Update Posted:
2010-12-08
First Post:
2010-08-12
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Fasting Conditions.
Sponsor:
Teva Pharmaceuticals USA
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2006-06
Start Date Type:
None
Primary Completion Date:
2006-08
Primary Completion Date Type:
ACTUAL
Completion Date:
2006-08
Completion Date Type:
ACTUAL
First Submit Date:
2010-08-12
First Submit QC Date:
None
Study First Post Date:
2010-08-16
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2010-09-15
Results First Submit QC Date:
None
Results First Post Date:
2010-10-07
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2010-11-22
Last Update Post Date:
2010-12-08
Last Update Post Date Type:
ESTIMATED